New treatment approach for Alzheimer's disease using a small molecule
SMALL MOLECULE THERAPEUTIC FOR ALZHEIMER'S DISEASE
This study is working on a new medication for Alzheimer's disease that aims to help the brain break down harmful proteins and improve thinking skills, with the hope that it can slow down the progression of the disease and offer patients a better quality of life.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Somatolynk, INC. NIH-funded |
| Lab location | 1 site (Edwardsville, United States) |
| Project ID | NIH-10695624 on NIH RePORTER |
What this research studies
This research focuses on developing a new small molecule therapeutic aimed at treating Alzheimer's disease by targeting the somatostatin receptor-4 (SSTR4) in the brain. The approach involves designing and screening compounds that can enhance the metabolism of amyloid-beta, a key factor in Alzheimer's pathology, while also improving cognitive function. The research employs advanced computer-aided drug design and an iterative optimization process to identify the most promising candidates for further development and eventual clinical trials. Patients may benefit from a novel treatment option that could slow disease progression and improve cognitive abilities.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease, particularly those in the early to moderate stages of the condition.
Not a fit: Patients with advanced Alzheimer's disease or those with other forms of dementia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option that may slow the progression of Alzheimer's disease and enhance cognitive function in patients.
How similar studies have performed: While targeting SSTR4 is a novel approach, similar strategies in Alzheimer's research have shown promise, indicating potential for success.
Where this research is happening
Edwardsville, United States
- Somatolynk, INC. — Edwardsville, United States (Active)
Researchers
- Principal investigator: Witt, Ken — Somatolynk, INC.
- Study coordinator: Witt, Ken
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.